HCC fast facts:

6th most common cancer

6th most commonly diagnosed cancer accounting for 4.7% of all new cancer cases1

Hepatocellular carcinoma represents 90% of primary liver cancers2

3rd largest cause of cancer deaths

3rd largest cause of cancer deaths worldwide1

Number 3 leading cause of cancer deaths globally, accounting for 8% of all cancer mortality in 20201

survival rate

5-year survival rate between 10-20%

830K deaths in 2020, with 1.1M projected in 20301

Hepatocellular carcinoma

The global incidence of liver cancer is increasing, growing 3% per year in Asia and Europe, and around 1-2% in the United States

Identifying HCC patients at very early stage (stage 0) is a huge clinical unmet need

Current imaging diagnostics offer poor sensitivity for small lesions (1-2cm)

Median’s eyonis™ HCC

Unrivalled AI/ML Software as Medical Device (SaMD) enabling very early HCC diagnosis with unprecedented performance

  • The only end-to-end AI/ML tech-based CADe/CADx SaMD for very early stage HCC

  • Indicated for the detection, localization, and characterization of small nodules below 2cm

  • Unprecedented sensitivity and specificity versus standard of care

  • A radiological CADe device is “intended to identify, mark, highlight or otherwise direct attention to portions of an image that may reveal abnormalities during interpretation of images by the clinician”. A CADx device is “intended to provide information beyond identifying abnormalities, such as an assessment of disease”. Source: FDA

    Additional indications

    Lung cancer

    Lung cancer screening (LCS) & incidental pulmonary nodules (IPN)

    About eyonis™

    Early diagnosis & treatment of cancer

    Latest news


    Median Technologies Announces Rebranding of iBiopsy®, Changes Name to eyonis™

    Median Technologies unveils a new identity, including a new name, logo, tagline for its iBiopsy® AI/ML tech-based suite of software as medical devices (SaMD) and business unit, as part of an extensive rebranding initiative. iBiopsy® becomes eyonis™.


    Median Technologies to speak at the Radiological Society of North America 2023 Annual Meeting, Nov. 26 – 30, Chicago, IL, USA

    AI Theater Presentation: “Transforming Cancer Diagnosis through End-to-End AI-Powered SaMD”


    First results of Median Technologies’ iBiopsy® HCC detection AI model developed on the PHELICAR Clinical Data Registry, to be presented at the ESMO Congress(Oct 20-24, 2023, Madrid, Spain)


    Median Technologies announces onboarding of all academic sites involved in the pivotal validation plan for iBiopsy® LCS CADe/CADx SaMD